Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...

PTC Therapeutics (NASDAQ:PTCT) reported top-line results from a 24-month interim analysis of the PIVOT-HD long-term extension (LTE) study evaluating Votoplam in Huntington’s disease, highlighting what ...

People affected by Huntington’s disease could at last benefit from the first treatment to slow the fatal neurodegenerative condition. Scientists from University College London (UCL) found patients ...

There’s an awareness walk coming up this weekend deals with a disease that steals mobility, memory and so much more from its ...

TAMPA, Fla. (WFLA) — For the first time, scientists have successfully treated someone suffering from Huntington’s disease, a fatal genetic illness with no cure. The Mayo Clinic reports that the ...

For decades, so many families have watched loved ones suffer from Huntington's disease, a neurodegenerative condition that progressively worsens over time. But now, there is finally a light at the end ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

Gene therapy is becoming a powerful way to treat challenging diseases that don’t respond to traditional treatments, and researchers now report the first success in modifying genes to slow Huntington’s ...

Huntington's disease is a devastating brain disorder that slowly robs people of movement, memory, and personality. It is caused by a toxic protein that builds in brain cells and ultimately kills them.

Prefer Newsweek on Google to see more of our trusted coverage when you search. People affected by Huntington’s disease could at last benefit from the first treatment to slow the fatal ...